Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL101 open-label extension in early Alzheimer's disease
2025-521107-42-00Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, open-label, single-arm trial of osugacestat in Alzheimer's disease (AD), sponsored by GSK. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence and severity of ARIA. Started Nov 2025; status: completed.
02
Drugs
osugacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-521107-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521107-42-00.